ABBV-974 is a selective androgen receptor degrader (SARD) under investigation for the treatment of androgen receptor (AR)-dependent diseases, particularly prostate cancer. It functions by binding to the androgen receptor and promoting its degradation, thereby inhibiting AR signaling more completely than traditional anti-androgens. This mechanism is especially relevant in castration-resistant prostate cancer (CRPC), where AR signaling often remains a key driver of disease progression despite standard therapies. The compound has shown potential in preclinical models to suppress tumor growth in prostate cancer cells that express wild-type or mutated forms of the androgen receptor, including those resistant to current treatments like enzalutamide or abiraterone. Its ability to degrade rather than just block the receptor may reduce the likelihood of resistance development and provide more durable responses. ABBV-974 is being explored in clinical trials to assess its safety, pharmacokinetics, and efficacy, both as a monotherapy and in combination with other agents targeting the androgen signaling pathway. Its development represents a promising approach in overcoming treatment resistance in advanced prostate cancer.